Adding Targeted Drug to Chemo Boosts Survival in Esophageal/GEJ Cancer
SAN FRANCISCO — Adding a Claudin (CLDN) inhibitor to chemotherapy significantly increased progression-free (PFS) and overall survival (OS) in locally advanced gastric/gastroesophageal junction (GEJ) cancer and CLDN 18.2 expression, a randomized trial showed. Median PFS increased from 8.67 months with modified FOLFOX chemotherapy to 10.61 months with the addition of investigational zolbetuximab. Median OS improved […]